Defective membrane interactions of familial Parkinson's disease mutant A30P α-Synuclein

Journal of Molecular Biology

Volumn 315, Issue 4, 2002, Pages 799-807

  Jo, Euijung ^a   Fuller, Nola ^b   Rand, R Peter ^b   St George Hyslop, Peter ^a,c   Fraser, Paul E ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b BROCK UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amphipathic helix; Lipid vesicles; Membrane binding; Parkinson's disease; synuclein

Indexed keywords

ALPHA SYNUCLEIN; DIMER; MUTANT PROTEIN; PHOSPHOLIPID; PROLINE; PROTEIN A30P; UNCLASSIFIED DRUG;

ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL DISEASE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE BINDING; MUTATION; NONHUMAN; PARKINSON DISEASE; PHOSPHOLIPID VESICLE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; ULTRACENTRIFUGATION; X RAY DIFFRACTION;

MURINAE;

EID: 0036307753     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2001.5269     Document Type: Article

References (53)

1. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch
2. The precursor protein of non-Abeta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system
3. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons
4. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
5. Autosomal dominant Parkinson's disease and alpha-synuclein
6. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
7. Alpha-synuclein in Lewy bodies
8. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease
9. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease
10. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia
11. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
12. Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases
13. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies
14. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies
15. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies
16. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein
17. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy
18. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy
19. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies
20. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders
21. Alpha synuclein in neurodegenerative disorders: Murderer or accomplice?
22. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease
23. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
24. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro
25. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation
26. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease
27. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
28. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
29. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation
30. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments
31. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
32. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis
33. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
34. Alpha-synuclein membrane interactions and lipid specificity
35. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis
36. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development
37. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
38. Synucleins in synaptic plasticity and neurodegenerative disorders
39. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins
40. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
41. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes
42. Characterization of the precursor protein of the non-Abeta component of senile plaques (NACP) in the human central nervous system
43. Aluminum-induced structural alterations of the precursor of the non-Aβ component of Alzheimer's disease amyloid
44. Familial Parkinson's disease. The awakening of alpha-synuclein
45. Alpha-synuclein - A link between Parkinson and Alzheimer diseases?
46. Effect of vesicle size on their interaction with class A amphipathic helical peptides
47. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations
48. Low-angle X-ray diffraction
49. An amphipathic alpha-helix at a membrane interface: A structural study using a novel X-ray diffraction method
50. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion
51. A simplification of the protein assay method of Lowry et al. which is more generally applicable
52. Hydration forces